Abstract Estrogen receptor (ER)-positive breast cancer treatment is based primarily on endocrine therapy. To dissect mechanisms of sensitivity to aromatase inhibitors in ER-positive breast cancer, we profiled tumor biopsies from 25 patients during neoadjuvant therapy using single-cell RNA sequencing, immune receptor sequencing and enhancer activity mapping. Malignant cells with high ER signaling and elevated activity of enhancers with ER binding sites were sensitive to treatment.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Villads
Contact Villads, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack